Importantly, tumorigenicity was enhanced for EGFR-amplified cells (median survival 102 versus 117 days, p = 0.0018, log-rank test), emphasizing the relevance of EGFR expression for the progression of GBM in vivo. The gene discussed is EGFR; the disease is glioblastoma.